Jan 3 2011
Golden Meditech Holdings Limited ("Golden Meditech" or the "Company," together with its subsidiary collectively as the "Group" - 801.HK), Mainland China's leading integrated healthcare enterprise, is pleased to announce that the Company has obtained the approvals from the Taiwan Stock Exchange and the Taiwan Securities and Futures Bureau for its proposed offering and listing of Taiwan Depositary Receipts ("TDR") on the Taiwan Stock Exchange. The Company will become the first Mainland Chinese healthcare enterprise to list its TDR on the Taiwan Stock Exchange.
The Company intends to offer 90 million TDR units (equivalent to 180 million ordinary Shares of the Company). A portion of the proceeds will fund the establishment of a representative office in Taiwan. In view of the rare opportunities arising from the Economic Cooperation Framework Agreement ("ECFA") so as to foster closer ties between industry counterparts on both sides of the Taiwan Strait, the Company is actively pursuing to strengthen its core businesses and market presence through Taiwan's talent advantage.
According to the Company's recently published interim results in accordance with Hong Kong Accounting Standards, the Group's revenue for the six month ended September 30th, 2010 amounted to HK$163 million with 24% growth relative to the previous corresponding period. Profit for the period amounted to HK$161 million with 170% growth relative to the previous interim reporting period.
Mr. Kam Yuen, the Company's Chairman and Chief Executive Officer pointed out that the rapid growth of the Group's hospital management business, the penetration of the Autologous Blood Recovery Systems into mid-tier hospitals and the substantial growth in medical accessories consumption all contributed to the increase in the Group's revenue for the period. The hospital management business accounted for 23% of the Group's total revenue at HK$38million.
Source:
Golden Meditech Holdings Limited
AI rollout in NHS hospitals faces major challenges